Skip to content
Joints & Immunity — mTOR inhibitorsATC L04AA18

Everolimus

Prescription only

mTOR inhibitor for transplant rejection and several cancers.

Starts working
Weeks
Half-life
About 30 hours
In use since
—
Pregnancy
Usually avoided

Overview

Everolimus is used at low doses to prevent organ rejection (Certican/Zortress) and at higher doses for breast, kidney, neuroendocrine tumours and tuberous sclerosis. The two uses use different products and doses.

How it works

Stops immune or tumour cell growth signals.

Everolimus belongs to the mTOR inhibitors. How mTOR inhibitors work: stop immune and cancer cells responding to growth signals.

Uses

  • Kidney or liver transplant rejection prevention
  • Hormone-positive breast cancer (with exemestane)
  • Kidney cancer
  • Neuroendocrine tumours
  • Tuberous sclerosis complex

Available as: tablet, dispersible tablet.

Typical dose

Adults
Oncology: 10 mg once a day. Transplant: 0.75–1 mg twice a day adjusted to levels.
Good to know
Do not swap the oncology and transplant products.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Mouth ulcers
  • Rash
  • Tiredness
  • Raised cholesterol and blood sugar
  • Swollen ankles

Serious — get medical help

Uncommon, but need prompt attention

  • Lung inflammation
  • Serious infections
  • Kidney impairment
  • Poor wound healing

Warnings

  • Dose depends on the indication; do not swap products
  • Mouth rinse with steroid solution prevents ulcers

Who should avoid it

  • Pregnancy
  • Severe liver impairment

Interactions

  • Ketoconazole, clarithromycin, ritonavir — much higher levels
  • Rifampicin, St John's wort — lower levels
  • Ciclosporin — raises everolimus levels
  • ACE inhibitors — higher angioedema risk
  • Live vaccines — avoid

Other medicines in the atlas that need care with Everolimus, grouped by the reason:

Reduced effectModerateWith Carbamazepine, Efavirenz, Enzalutamide, Griseofulvin, Modafinil and 5 more

Enzyme induction lowers levels of this medicine, which may stop it working.

What's usually done: Monitor effect; dose changes or alternatives may be needed. The effect lasts weeks after stopping the inducer.

Raised drug levelsModerateWith Clarithromycin, Darunavir, Erythromycin, Itraconazole, Lopinavir-ritonavir and 2 more

Blocking CYP3A4 increases levels of this medicine, so side effects become more likely.

What's usually done: A dose reduction, alternative or extra monitoring may be needed.

Check Everolimus against your own medicines

Using it safely

Alcohol
Best to limit. Alcohol adds to mouth sores and liver strain.
Food and drink
Take consistently with or without food; avoid grapefruit.
If you miss a dose
Take within 6 hours; otherwise skip.
Stopping it
Only on advice of your specialist.
Driving
Tiredness may affect driving.
Tests and checks
Everolimus levels (transplant); Lipids; Glucose; Kidney function; Mouth ulcers
If too much is taken
Seek advice.
Storage
Room temperature.
Legal status
United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HAustralia: Prescription only (Schedule 4)

Pregnancy and breastfeeding

Pregnancy

Usually avoided

Avoid; effective contraception advised.

Breastfeeding

Usually avoided

Avoid.

Special groups

Kidney disease
Dose by levels or indication.
Liver disease
Reduce the dose in impairment.
Older adults
Use caution.

Brand names

United States
Afinitor, Zortress
United Kingdom
Afinitor, Certican
India
Afinitor, Certican, Everolimus (generic)
Australia
Afinitor, Certican

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

Common questions

Do I need a prescription for Everolimus?

Yes — Everolimus is prescription-only in most countries.

Can I take Everolimus during pregnancy?

Usually avoided. Avoid; effective contraception advised. Always check with a doctor or midwife.

How quickly does Everolimus work?

Weeks.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.